GastroPlus在考特殊給藥途徑的應用文章 （2012—2020）

導  讀

凡默谷技術部精取了2012-2020年10月GastroPlus在特殊給藥途徑領域的應用文章19篇。

其中編號1-4的文章是2019年8月-2020年10月新增的文章。

希望對您的業務或專業學習有所幫助。內容如下：

1.   采用生理藥代動力學PBPK模型支持眼科懸浮制劑的開發

Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.

Le Merdy M, Tan ML, Babiskin AH, Zhao L. AAPS J. (2020) 22: 26. IF= 3.737

2.  用于利福平經皮遞送的囊狀彈性脂質體：體外，體內和GastroPlus? 計算機預測研究

Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus? prediction studies.

Hussain A, Altamimi MA, Alshehri S, Imam SS, Singh SK. Eur J Pharm Sci. Volume 151, 1 August 2020, 105411. IF=3.616

3.  采用生理藥代動力學PBPK建模，以了解利培酮口腔崩解膜劑的吸收機理

Physiologically based pharmacokinetic modeling to understand the absorption of risperidone orodispersible film.

Fang Chen, Hongrui Liu, Bing Wang, Liuliu Yang, Weimin Cai, Zheng Jiao, Zhou Yang, Yusheng Chen, Yingjun Quan, Xiaoqiang Xiang, Hao Wang. Front. Pharmacol.,03 February 2020. IF=4.545

4.   將吸入式氣溶膠劑量測定法與生理藥代動力學PBPK模型進行橋接，以評估尼古丁傳遞系統及其他物質的毒理

Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond.

Kolli AR, Kuczaj AK, Martin F, Hayes AW, Peitsch MC, Hoeng J. Crit Rev Toxicol. Volume 49, 2019 - Issue 9. IF=4.257

5.  考察吸入粉霧劑DPI對濕度的敏感性：綜合的體外-計算機預測進行風險的評估

Insights into DPI sensitivity to humidity: An integrated in-vitro-in-silico risk-assessment. 

Radivojev S, Pinto JT, Fr?hlich E, Paudel A. J Drug Deliv Sci Technol.May 31, 2019. IF=2.606

6.   采用眼部機制性吸收建模與模擬，理解制劑處方性質對家兔眼部生物利用度的影響-以地塞米松Dexamethasone懸浮液為例

Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Le Merdy M, Fan J, Bolger MB, Lukacova V, Spires J, Tsakalozou E, Patel V, Xu L, Stewart S, Chockalingam A, Narayanasamy S, Rouse R, Matta M, Babiskin AH, Kozak D. AAPS J. May 20, 2019. IF=3.545

7.  采用計算機預測的方法開發仿制藥-裝置組合的口服吸入制劑

In silico methods for development of generic drug‐device combination orally inhaled drug products. 

Walenga RL, Babiskin AH, Zhao L. CPT Pharmacometrics Syst Pharmacol. May 1, 2019. CiteScore=3.24

8.   眼部生物藥劑學：建模和模擬方法對局部眼科制劑處方開發的影響

Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development. 

Gukasyan HJ, Hailu S, Karami TK, Graham R. Drug Discov Today. Apr 5, 2019. IF=7.321

9.   用于了解吸入制劑在肺部暴露的實驗和機制性計算模型的進展

Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. 

B?ckman P, Arora S, Couet W, Forbes B, de Kruijf W, Paudel A. Eur J Pharm Sci. 2018 Feb 15;113:41-52. IF=3.616

10.  用現代標準評價2-乙基己基丙烯酸酯的皮膚致癌性研究

Critical Evaluation of 2-Ethylhexyl Acrylate Dermal Carcinogenicity Studies Using Contemporary Criteria. 

Murphy S, Ellis-Hutchings R, Finch L, Welz S, Wiench K.Toxicol Lett. Sep 15, 2018. IF=3.569

11.  化妝品安全評估中毒理學關注內部閾值（iTTC）面臨的挑戰：化妝品歐洲iTTC研討會的相關討論要點

Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop. 

Ellison CA, Blackburn KL, Carmichael PL, Clewell HJ 3rd, Cronin MTD, Desprez B, Escher SE, Ferguson SS, Gregoire SL, Hewitt NJ, Hollnagel HM, Klaric M, Patel A, Salhi S, Schepky A, Schmitt BG, Wambaugh JF, Worth A. Regul Toxicol Pharmacol. Jan 28, 2019. IF=2.652

12.  聯用計算機模擬平臺：計算流體動力學CFD和生理藥代動力學PBPK的建模

Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling. 

Vulovi? A, ?u?ter?i? T, Cviji? S, Ibri? S, Filipovi? N. Eur J Pharm Sci. 2018 Feb 15;113:171-184. IF=3.616

13.  肺部沉積和體外滲透對預測布地奈德吸入制劑血漿濃度的影響

Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation. 

Salar-Behzadi S, Wu S, Mercuri A, Meindl C, Stranzinger S, Fr?hlich E. Int J Pharm. 2017 Oct 30;532(1):337-344. IF=4.845

14.  用于表征口服吸入制劑PK的定量藥理學模型

Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. 

Borghardt JM, Weber B, Staab A, Kloft C. (2015). AAPS J. Apr 7. IF=3.737

15.  開發和驗證雌二醇經皮給藥系統的體內外相關性IVIVC模型

Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems. 

Yang Y, Manda P, Pavurala N, Khan MA, Krishnaiah YS. (2015). J Control Release. May 13;210:58-66. IF=7.727

16.  吸入制劑技術的發展進程：理解治療的挑戰，預測臨床的療效，并設計最佳的吸入制劑

Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product. 

B?ckman P, Adelmann H, Petersson G, Jones CB. (2014) Clin Pharmacol Ther. 95(5):509-20. IF=6.565

17.  針對舌下給藥的新型口腔房室吸收和轉運模型的開發：以唑吡坦作為闡述的案例

Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem. 

Xia B, Yang Z, Zhou H, Lukacova V, Zhu W, Milewski M, Kesisoglou F. (2015) AAPS J. Feb 26.IF=3.737

18.  普萘洛爾舌下緩沖片劑（Promptol?）的臨床藥代動力學-使用新的基于生理學模型進行吸收和處置的評價

Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol?)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition. 

Wang Y, Wang Z, Zuo Z, Tomlinson B, Lee BT, Bolger MB, Chow MS. (2013). AAPS J. Apr 19.IF=3.737.

19.  Risperdal?和 Consta? 微球體外釋放的比較

Comparison of in vitro–in vivo release of Risperdal? Consta? microspheres. 

Rawata A, Bhardwajb U, Burgess DJ. (2012). Int. J. Pharm. 434(1):115-21.IF=4.845

點擊查看其他文獻

• GastroPlus在FDA等法規部門的應用文章(2016-2020)